Ranked fourth among the Indian Pharmaceutical companies, Zydus Cadila has been maintaining its reputation when it comes to offering innovative solutions. In times of Coronavirus pandemic, it has emerged as a front runner in terms of vaccine research and development. Simultaneously, the company has remained focused on strengthening its portfolio in other key segments. It is clearly evident from the recent US FDA approvals for its Cancer and HIV medications. In India, it is very close to get the nod from CDSCO for its innovative anti-COVID vaccine, named ZyCov-D.
ZyCov-D, Generic Emtricitabine and Tenofovir Disoproxil Fumarate & Pemetrexed
As Zydus Cadila seeks approval for ZyCov-D, which could prove to be a game changer in the global fight against Coronavirus, it is only natural to expert its stock value to boost. There is a strong R&D behind its success which is always a great asset for any Pharmaceutical manufacturer. Considering ZyCov-D which is unique by virtue of being the first ever plasmid DNA vaccine for human use. Being needle free would add to the convenience. While ZyCov-D sets off a new trend in the global vaccination program against Coronavirus, the US FDA approval for generic Emtricitabine and Tenofovir Disoproxil Fumarate tablets by Zydus Cadila is a major plus. This comes almost immediately after the company bagging tentative approval by the FDA to market generic Pemetrexed. Overall these recent developments clearly indicate the growing prominence and global footprint of the company. This must serve as a great motivation to the other upcoming Indian Pharmaceutical companies.
An innovative vaccine development project with ZyCov-D
Back in 2020 when the other Pharmaceutical manufacturers were only focusing on collaborating with the global innovators, Zydus Cadila has a different vision. It was forthcoming and bold at many levels which ultimately gave the company much needed elevation on the global platform. ZyCov-D is a three-dose intradermal vaccine. Its needlefree system not only adds to the convenience, but also potentially reduces certain side effects. The plasmid DNA technology used in the development of ZyCov-D can also be credited for its effectiveness against new mutations.
As per the company’s press releases, the phase 1 and phase 2 trials produced results indicating robust efficacy and safety profile of ZyCov-D. Primary efficacy of 66.6 percent in the interim analysis proved to be a positive outcome. The phase 3 data which is expected in the next four months or so will be highly anticipated and closely studied for finer assessment. For now, it is the CDSCO approval for its emergency use that will kick start the production at a faster pace. As per Sharvil Patel, MD, Zydus Cadila, the production target is 10 Crore vaccine doses in a year. Apart from adults, ZyCov-D can also be administered to the 12 to 18 years age group adolescents. There is lot more to expect and hope from the company’s ongoing research and development activity. Zydus Cadila is a true reflection of the Indian dream of driving global innovation.
